BeiGene, Ltd.
https://www.beigene.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From BeiGene, Ltd.
Novartis Drops BeiGene PD-1 Asset Tevimbra As Drug Wins Esophageal Cancer Nod In Europe
The Swiss drug maker’s decision to give back rights to tislelizumab means BeiGene goes without the potentially $1.55bn in milestone payments the companies had agreed to in early 2021.
Daiichi Sankyo Comes Out Swinging At WCLC As ADCs Steal Show
The Japanese drug maker gave multiple presentations on AstraZeneca-partnered Enhertu and other deruxtecan-based ADCs. Plus Gilead presented data on Trodelvy, Amgen showed early frontline data for Lumakras, and J&J’s EGFR-directed bispecific Rybrevant showed a 50% ORR in heavily pretreated patients.
BeiGene Among Chinese Firms Eyeing Less Crowded SCLC Sector In US Trials
BeiGene, Junshi, Henlius are studying their PD-1, TIGIT and BTLA-targeting assets in US trials for the relatively less crowded indication of small cell lung cancer.
Chinese PD-1s Eye US Approvals Despite Lack Of Action Dates
Although Novartis/BeiGene’s tislelizumab and Coherus /Junshi’s toripalimab have not received a new Prescription Drug User Fee Act (PDUFA) decision date for their biologics license applications in the US, the companies remain hopeful that potential approvals will be granted in the third quarter at the earliest.
Company Information
- Industry
- Biotechnology
- In Vitro Diagnostics
- Pharmaceuticals
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
-
Large Molecule
- Antibodies
-
Drug Discovery Tools
- Bioinformatics
- Other Names / Subsidiaries
-
- MapKure, LLC
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice